Validation of the Onset of Effect Questionnaire in Participants With Chronic Obstructive Pulmonary Disease.

Onset of Effect Questionnaire chronic obstructive pulmonary disease patient-reported outcome

Journal

Chronic obstructive pulmonary diseases (Miami, Fla.)
ISSN: 2372-952X
Titre abrégé: Chronic Obstr Pulm Dis
Pays: United States
ID NLM: 101635411

Informations de publication

Date de publication:
07 May 2024
Historique:
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

Patient perception of medication onset of effect is important for adherence. Although the Onset of Effect Questionnaire (OEQ) has been validated in patients with asthma, it has not been evaluated in patients with chronic obstructive pulmonary disease (COPD). This study evaluated the COPD-OEQ in patients with COPD. Two analyses (qualitative and quantitative) were conducted to assess the content validity and psychometric properties of the COPD-OEQ in participants with COPD. In the qualitative analysis, interviews assessed content validity by concept elicitation (CE) and cognitive interviewing (CI). CE included questions to understand patient experience related to onset of medication effect. CI included completion of the COPD-OEQ and assessment of the COPD-OEQ items, response options, and instructions. During the 2-week quantitative analysis, 2 versions of the COPD-OEQ (Weekly and Daily) were administered to assess test-retest reliability, construct validity, and known-groups validity. The qualitative analysis demonstrated that 3 of the 5 COPD-OEQ items were relevant and understood as intended. Qualitative findings demonstrated inconsistent evidence that the COPD-OEQ Weekly and Daily were reliable and valid measures in participants with COPD. Test-retest reliability was observed for the COPD-OEQ Weekly and Daily; however, construct validitywas weak and demonstrated inconsistent correlations among COPD-OEQ items. Overall, known-groups validity was not demonstrated. The weak evidence from the quantitative analysis of the COPD-OEQ Weekly and Daily tools does not support use of the OEQ in general COPD. The study supports the content validity for the assessment of perceived onset of effect in patients with COPD.

Sections du résumé

Background UNASSIGNED
Patient perception of medication onset of effect is important for adherence. Although the Onset of Effect Questionnaire (OEQ) has been validated in patients with asthma, it has not been evaluated in patients with chronic obstructive pulmonary disease (COPD). This study evaluated the COPD-OEQ in patients with COPD.
Methods UNASSIGNED
Two analyses (qualitative and quantitative) were conducted to assess the content validity and psychometric properties of the COPD-OEQ in participants with COPD. In the qualitative analysis, interviews assessed content validity by concept elicitation (CE) and cognitive interviewing (CI). CE included questions to understand patient experience related to onset of medication effect. CI included completion of the COPD-OEQ and assessment of the COPD-OEQ items, response options, and instructions. During the 2-week quantitative analysis, 2 versions of the COPD-OEQ (Weekly and Daily) were administered to assess test-retest reliability, construct validity, and known-groups validity.
Results UNASSIGNED
The qualitative analysis demonstrated that 3 of the 5 COPD-OEQ items were relevant and understood as intended. Qualitative findings demonstrated inconsistent evidence that the COPD-OEQ Weekly and Daily were reliable and valid measures in participants with COPD. Test-retest reliability was observed for the COPD-OEQ Weekly and Daily; however, construct validitywas weak and demonstrated inconsistent correlations among COPD-OEQ items. Overall, known-groups validity was not demonstrated.
Conclusion UNASSIGNED
The weak evidence from the quantitative analysis of the COPD-OEQ Weekly and Daily tools does not support use of the OEQ in general COPD. The study supports the content validity for the assessment of perceived onset of effect in patients with COPD.

Identifiants

pubmed: 38722709
doi: 10.15326/jcopdf.2023.0485
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : AstraZeneca
Pays : United States

Informations de copyright

JCOPDF © 2024.

Auteurs

Charlie Strange (C)

Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina, United States.

Barry J Make (BJ)

Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, United States.

Frank J Trudo (FJ)

BioPharmaceuticals Medical, AstraZeneca, Wilmington, Deleware, United States.

Gale Harding (G)

Evidera, Bethesda, Maryland, United States.

Danielle Rodriguez (D)

Evidera, Seattle, Washington, United States.

James M Eudicone (JM)

BioPharmaceuticals Medical, AstraZeneca, Wilmington, Deleware, United States.

Norbert Feigler (N)

BioPharmaceuticals Medical, AstraZeneca, Wilmington, Deleware, United States.

Hitesh N Gandhi (HN)

Alexion, AstraZeneca Rare Disease, Wilmington, Delaware, United States.

Classifications MeSH